节拍性化疗联合TACE治疗原发性肝癌的临床观察  

Clinical study of TACE combined with metronomic chemotherapy for primary liver cancer

作　　者：尹晓东[1] 嵇晓艳[1] 张海滨[1] 何开玲[1] 

机构地区：[1]滨海县人民医院肿瘤科,江苏滨海224500

出　　处：《临床肿瘤学杂志》2009年第6期557-559,共3页Chinese Clinical Oncology

摘　　要：目的:探讨节拍性化疗(metronomic chemotherapy)联合肝动脉化疗栓塞(TACE)对原发性肝癌(PHC)的疗效及毒副反应。方法:经临床诊断的原发性肝癌41例患者分为A、B两组。A组21例,TACE间歇期接受节拍性化疗,即每次TACE术后1周给予替加氟100mg口服,每日1次;环磷酰胺50mg口服,每日1次,持续口服2～3周,休息1周;2～3次TACE术后,持续节拍性化疗3～4个月。B组20例,仅用TACE治疗。每月复查血常规、肝功能、B超、CT和AFP等,并评价疗效。结果:A、B两组患者中位生存期分别为18个月和12个月,A组近期疗效为76%,B组近期疗效为45%,差异有显著性(P<0.05)。A组1年存活率为60%,B组为33%,两组差异显著(P<0.05)。两组毒副反应相似,无显著性差异。结论:采用TA-CE联合节拍性化疗治疗原发性肝癌,能够提高近期疗效,且不增加毒副反应。Objective ： To study the effect and toxicity of metronomic chemotherapy combined with transcatheter arteria chemo- embolization（TACE） in patients with primary liver cancer（PHC）. Methods：Forty-one cases of PHC were randomly divided into two groups. Group A（ n = 21 ） were treated with TACE combined with metronomic chemotherapy, and group B （n = 20） were treated with TACE alone. All these patients were followed up with AFP test, Ultrasound and CT in one month. Results：The median survival period was 18 months in combination group and 12 months in TACE group. The short-term therapeutic effect was 76% in group A, and 45% in group B. There was a significant difference between them. The survival probability of one year of group A was 60% , while group B was 33%. There was also a significant difference between them. Conclusion：The therapy of TACE combined with metronomic＇, chemo- therapy could increase the short-term therapeutic effects while not raise the toxicity.

关 键 词：原发性肝癌 肝动脉化疗栓塞 节拍性化疗 联合疗法 

分 类 号：R735.7[医药卫生—肿瘤]